Ongoing Clinical Trials

Based on the unique mechanism of action of TTFields, multiple clinical studies investigating the efficacy and safety of TTFields in a range of cancer types have been initiated, including1-8:

Clinic Trial Phase Status Estimated Enrollment Estimated Primary Completion Date

A phase III study of TTFields following stereotactic radiosurgery (SRS) for the treatment of 1-10 brain metastases from non-small cell lung cancer (NSCLC) more…

Phase III Recruiting 270 September 2022

A phase III study of TTFields concomitant with standard of care therapies for the treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure more…

Phase III Active, not recruiting 276 September 2023

A phase III study of TTFields concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer more…

Phase III Active, not recruiting 540 September 2023

A phase III study of TTFields concomitant with gemcitabine and nab-paclitaxel as the front-line treatment of unresectable, locally advanced pancreatic adenocarcinoma more…

Phase III Recruiting 556 September 2024

A phase III study of TTFields concomitant with radiotherapy and temozolomide for the treatment of newly diagnosed glioblastoma (GBM) more…

Phase III Recruiting 950 August 2024

A phase II study of TTFields concomitant with XELOX as the first-line treatment of unresectable, locally advanced or metastatic gastroesophageal junction (GEJ) or gastric (GC) adenocarcinoma more…

Phase II Active, not recruiting 28 September 2021

A phase II study of TTFields delivered through high intensity arrays for the treatment of recurrent glioblastoma (GBM) more…

Phase II Recruiting 25 January 2022

A phase II study of TTFields concomitant with pembrolizumab as the first-line treatment of advanced or metastatic intrathoracic, PD-L1 positive non-small cell lung cancer (NSCLC) more…

Phase II Recruiting 66 July 2024

References:

  1. National Institutes of Health U.S National Library of Medicine. METIS trial. Available at: https://clinicaltrials.gov/ct2/show/NCT02831959. Accessed 2 August, 2022.
  2. National Institutes of Health U.S National Library of Medicine. LUNAR trial. Available at: https://clinicaltrials.gov/ct2/show/NCT02973789. Accessed 2 August, 2022.
  3. National Institutes of Health U.S National Library of Medicine. ENGOT-ov50/GOG-3029/INNOVATE-3 trial. Available at: https://clinicaltrials.gov/ct2/show/NCT03940196. Accessed 2 August, 2022.
  4. National Institutes of Health U.S National Library of Medicine. PANOVA-3 trial. Available at: https://clinicaltrials.gov/ct2/show/NCT03377491. Accessed 2 August, 2022.
  5. National Institutes of Health U.S National Library of Medicine. TRIDENT trial. Available at: https://clinicaltrials.gov/ct2/show/NCT04471844. Accessed 2 August, 2022.
  6. National Institutes of Health U.S National Library of Medicine. EF-31/ZL-8301-001 trial. Available at: https://clinicaltrials.gov/ct2/show/NCT04281576. Accessed 2 August, 2022.
  7. National Institutes of Health U.S National Library of Medicine. EF-33 trial. Available at: https://clinicaltrials.gov/ct2/show/NCT04492163. Accessed 2 August, 2022.
  8. National Institutes of Health U.S National Library of Medicine. KEYNOTE B36 trial. Available at: https://clinicaltrials.gov/ct2/show/NCT04892472. Accessed 2 August, 2022.
Back to Top